[an error occurred while processing this directive]|[an error occurred while processing this directive]
miRNAs与非小细胞肺癌EGFR突变及放疗相关性研究进展
许齐真, 张大昕
150001 哈尔滨医科大学附属第一医院肿瘤一科(许齐真现单位:福建医科大学附属协和医院放疗科)
Research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy in non-small cell lung cancer
Xu Qizhen,Zhang Daxin
FirstDepartment of Oncology,First Affiliated Hospital of Harbin Medical University,Harbin 150001,China(Xu QZ new unit:Department of Radiation Oncology,Affiliated Union Hospital of Fujian Medical University)
Abstract： Epidermal growth factor receptor (EGFR) is most popular in targeted therapy for non-small cell lung cancer (NSCLC). In recent years, there have been a great number of molecular biology studies of EGFR. Radiotherapy is well-known as a traditional and important treatment for NSCLC, and the treatment outcome is associated with EGFR mutation and overexpression. Phase Ⅲ trials are needed to evaluate the effect of a combination of radiotherapy and EGFR-tyrosine kinase inhibitor (EGFR-TKI) in the treatment of NSCLC. MicroRNAs (miRNAs) can modulate tumor-associated gene expression and influence the biological process of tumor. Recent studies have demonstrated that miRNAs play a positive or negative role in EGFR mutation, EGFR-TKI treatment, and radiotherapy, which mechanism has been partially clarified. In this article, we review the research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy, so as to provide the latest evidence for the application of miRNAs in the combination of radiotherapy and EGFR-TKI for the treatment of NSCLC.
Xu Qizhen,Zhang Daxin. Research advances in the association of miRNAs with EGFR mutation, EGFR-TKI, and radiotherapy in non-small cell lung cancer[J]. Chinese Journal of Radiation Oncology, 2017, 26(10): 1222-1226.
[1] Ferlay J,Soerjomataram I,Dikshit R,et al. Cancer incidence and mortality worldwide:sources,methods and major patterns in GLOBOCAN 2012[J].Int J Cancer,2015,136(5):E359-386.DOI:10.1002/ijc.29210. [2] Torre LA,Bray F,Siegel RL,et al. Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.DOI:10.3322/caac.21262. [3] Rolfo C,Chacartegui J,Giallombardo M,et al.71P Exosomes isolated in plasma of non-small cell lung cancer patients contain microRNA related to the EGFR pathway:proof of concept[J].J Thorac Oncol,2016,11(4):S85.DOI:10.1016/S1556-0864(16)30184-8. [4] Qin Q,Wei FR,Zhang JB,et al. MiR-134 inhibits non-small cell lung cancer growth by targeting the epidermal growth factor receptor[J].J Cell Mol Med,2016,20(10):1974-1983.DOI:10.1111/jcmm.12889. [5] Landi MT,Zhao YD,Rotunno M,et al. MicroRNA expression differentiates histology and predicts survival of lung cancer[J].Clin Cancer Res,2010,16(2):430-441.DOI:10.1158/1078-0432.CCR-09-1736. [6] Wang LK,Hsiao TH,Hong TM,et al. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma[J].PLoS One,2014,9(5):e96765.DOI:10.1371/journal.pone.0096765. [7] Lan D,Zhang X,He RQ,et al. MiR-133a is downregulated in non-small cell lung cancer:a study of clinical significance[J].Eur J Med Res,2015,20:50.DOI:10.1186/s40001-015-0139-z. [8] Zhu KG,Ding HY,Wang WG,et al. Tumor-suppressive miR-218-5p inhibits cancer cell proliferation and migration via EGFR in non-small cell lung cancer[J].Oncotarget,2016,7(19):28075-28085.DOI:10.18632/oncotarget.8576. [9] Li J,Wang HY,Ke HG,et al. MiR-129 regulates MMP9 to control metastasis of non-small cell lung cancer[J].Tumour Biol,2015,36(8):5785-5790.DOI:10.1007/s13277-015-3247-z. [10] Mataki H,Seki N,Chiyomaru T,et al. Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR oncogenic signaling in lung squamous cell carcinoma[J].Int J Oncol,2015,46(3):1039-1050.DOI:10.3892/ijo.2014.2802. [11] Zhang HB,Sun LC,Ling L,et al. MiR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor[J].Exp Ther Med,2016,12(3):1795-1802.DOI:10.3892/etm.2016.3555. [12] Gasparini P,Cascione L,Landi L,et al. MicroRNA classifiers are powerful diagnostic/prognostic tools in ALK-,EGFR-,and KRAS-driven lung cancers[J].Proc Natl Acad Sci USA,2015,112(48):14924-14929.DOI:10.1073/pnas.1520329112. [13] Remon J,Alvarez-Berdugo D,Majem M,et al.miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers[J].Clin Transl Oncol,2016,18(2):153-159.DOI:10.1007/s12094-015-1347-2. [14] Ma YH,Xu PQ,Mi YJ,et al. Plasma miRNA alterations between NSCLC patients harboring Del19 and L858R EGFR mutations[J].Oncotarget,2016,7(34):54965-54972.DOI:10.18632/oncotarget.10829. [15] Chiou YH,Liou SH,Wong RH,et al. Nickel may contribute to EGFR mutation and synergistically promotes tumor invasion in EGFR-mutated lung cancer via nickel-induced microRNA-21 expression[J].Toxicol Lett,2015,237(1):46-54.DOI:10.1016/j.toxlet.2015.05.019. [16] Okudela K,Suzuki T,Umeda S,et al. A comprehensive search for microRNAs with expression profiles modulated by oncogenic KRAS:potential involvement of miR-31 in lung carcinogenesis[J].Oncol Rep,2014,32(4):1374-1384.DOI:10.3892/or.2014.3339. [17] Guo YH,Zhang C,Shi J,et al. Abnormal activation of the EGFR signaling pathway mediates the downregulation of miR-145 through the ERK1/2 in non-small cell lung cancer[J].Oncol Rep,2014,31(4):1940-1946.DOI:10.3892/or.2014.3021. [18] Li JY,Li XF,Ren SX,et al. MiR-200c overexpression is associated with better efficacy of EGFR-TKIs in non-small cell lung cancer patients with EGFR wild-type[J].Oncotarget,2014,5(17):7902-7916.DOI:10.18632/oncotarget.2302. [19] Zhen Q,Liu J,Gao L,et al. MicroRNA-200a Targets EGFR and c-Met to Inhibit Migration,invasion,and gefitinib resistance in non-small cell lung cancer[J].Cytogenet Genome Res,2015,146(1):1-8.DOI:10.1159/000434741. [20] Stahlhut C,Slack FJ.Combinatorial Action of MicroRNAs let-7 and miR-34 effectively synergizes with erlotinib to suppress non-small cell lung cancer cell proliferation[J].Cell Cycle,2015,14(13):2171-2180.DOI:10.1080/15384101.2014.1003008. [21] Zhou JY,Chen X,Zhao J,et al. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET[J].Cancer Lett,2014,351(2):265-271.DOI:10.1016/j.canlet.2014.06.010. [22] Park KS,Raffeld M,Moon YW,et al. CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistance[J].J Clin Invest,2014,124(7):3003-3015.DOI:10.1172/JCI73048. [23] Gao Y,Fan XW,Li WN,et al. MiR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124[J].Biochem Biophys Res Commun,2014,446(1):179-186.DOI:10.1016/j.bbrc.2014.02.073. [24] Ge XJ,Zheng LM,Huang M,et al. MicroRNA expression profiles associated with acquired gefitinib-resistance in human lung adenocarcinoma cells[J].Mol Med Rep,2015,11(1):333-340.DOI:10.3892/mmr.2014.2757. [25] Park DH,Jeon HS,Lee SY,et al. MicroRNA-146a inhibits epithelial mesenchymal transition in non-small cell lung cancer by targeting insulin receptor substrate 2[J].Int J Oncol,2015,47(4):1545-1553.DOI:10.3892/ijo.2015.3111. [26] Shen H,Liu JY,Wang R,et al. Fulvestrant increases gefitinib sensitivity in non-small cell lung cancer cells by upregulating let-7c expression[J].Biomed Pharmacother,2014,68(3):307-313.DOI:10.1016/j.biopha.2013.10.007. [27] Lee CG,McCarthy S,Gruidl M,et al. MicroRNA-147 induces a mesenchymal-to-epithelial transition (MET) and reverses EGFR inhibitor resistance[J].PLoS One,2014,9(1):e84597.DOI:10.1371/journal.pone.0084597. [28] Li B,Ren SX,Li XF,et al. MiR-21 overexpression is associated with acquired resistance of EGFR-TKI in non-small cell lung cancer[J].Lung Cancer,2014,83(2):146-153.DOI:10.1016/j.lungcan.2013.11.003. [29] Shen H,Zhu F,Liu JY,et al. Alteration in Mir-21/PTEN expression modulates gefitinib resistance in non-small cell lung cancer[J].PLoS One,2014,9(7):e103305.DOI:10.1371/journal.pone.0103305. [30] Wang SH,Su XM,Bai H,et al. Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation[J].J Hematol Oncol,2015,8:127.DOI:10.1186/s13045-015-0210-9. [31] Chen X,Zhu LJ,Ma Z,et al. Oncogenic miR-9 is a target of erlotinib in NSCLCs[J].Sci Rep,2015,5:17031.DOI:10.1038/srep17031. [32] Kitamura K,Seike M,Okano T,et al. MiR-134/487b/655 cluster regulates TGF-β-induced epithelial-mesenchymal transition and drug resistance to gefitinib by targeting MAGI2 in lung adenocarcinoma cells[J].Mol Cancer Ther,2014,13(2):444-453.DOI:10.1158/1535-7163.MCT-13-0448. [33] Dinh TKT,Fendler W,Chalubińska-Fendler J,et al. Circulating miR-29a and miR-150 correlate with delivered dose during thoracic radiation therapy for non-small cell lung cancer[J].Radiat Oncol,2016,11(1):61.DOI:10.1186/s13014-016-0636-4. [34] Xu T,Liao ZX,O′Reilly MS,et al. Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer[J].Radiother Oncol,2014,113(3):379-384.DOI:10.1016/j.radonc.2014.11.006. [35] Jiang Y,Chen X,Tian W,et al. The role of TGF-β1-miR-21-ROS pathway in bystander responses induced by irradiated non-small-cell lung cancer cells[J].Br J Cancer,2014,111(4):772-780.DOI:10.1038/bjc.2014.368. [36] Liu G,Li Y,Gao XG.Overexpression of microRNA-133b sensitizes non-small cell lung cancer cells to irradiation through the inhibition of glycolysis[J].Oncol Lett,2016,11(4):2903-2908.DOI:10.3892/ol.2016.4316. [37] Cortez MA,Valdecanas D,Niknam S,et al. In Vivo delivery of miR-34a sensitizes lung tumors to radiation through RAD51 regulation[J].Mol Ther Nucleic Acids,2015,4:e270.DOI:10.1038/mtna.2015.47. [38] Lan FM,Yue X,Ren G,et al. MiR-15a/16 enhances radiation sensitivity of non-small cell lung cancer cells by targeting the TLR1/NF-κB signaling pathway[J].Int J Radiat Oncol Biol Phys,2015,91(1):73-81.DOI:10.1016/j.ijrobp.2014.09.021. [39] Ma DB,Jia H,Qin MM,et al. MiR-122 induces radiosensitization in non-small cell lung cancer cell line[J].Int J Mol Sci,2015,16(9):22137-22150.DOI:10.3390/ijms160922137. [40] Cortez MA,Valdecanas D,Zhang XC,et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer[J].Mol Ther,2014,22(8):1494-1503.DOI:10.1038/mt.2014.79. [41] Zhang JH,Zhang CL,Hu L,et al. Abnormal expression of miR-21 and miR-95 in cancer stem-like cells is associated with radioresistance of lung cancer[J].Cancer Invest,2015,33(5):165-171.DOI:10.3109/07357907.2015.1019676. [42] Ma YF,Xia H,Liu Y,et al. Silencing miR-21 sensitizes non-small cell lung cancer A549 cells to ionizing radiation through inhibition of PI3K/Akt[J].Biomed Res Int,2014,2014:617868.DOI:10.1155/2014/617868. [43] Ma W,Ma CN,Li XD,et al. Examining the effect of gene reduction in miR-95 and enhanced radiosensitivity in non-small cell lung cancer[J].Cancer Gene Ther,2016,23(2-3):66-71.DOI:10.1038/cgt.2016.2. [44] Chen XC,Chen SM,Hang WJ,et al. MiR-95 induces proliferation and chemo-or radioresistance through directly targeting sorting nexin1(SNX1) in non-small cell lung cancer[J].Biomed Pharmacother,2014,68(5):589-595.DOI:10.1016/j.biopha.2014.04.008. [45] Tang YT,Cui YY,Li ZP,et al. Radiation-induced miR-208a increases the proliferation and radioresistance by targeting p21 in human lung cancer cells[J].J Exp Clin Cancer Res,2016,35(1):7.DOI:10.1186/s13046-016-0285-3. [46] Shen ZT,Wu XH,Wang Z,et al. Effect of miR-18a overexpression on the radiosensitivity of non-small cell lung cancer[J].Int J Clin Exp Pathol,2015,8(1):643-648. [47] He ZW,Liu Y,Xiao B,et al. MiR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression[J].Biochem Biophys Res Commun,2015,457(3):235-241.DOI:10.1016/j.bbrc.2014.12.094.
2017, Vol. 26 
